Beigene logo

BGNE - Beigene News Story

$322 18.7  6.2%

Last Trade - 11/05/21

Sector
Healthcare
Size
Large Cap
Market Cap £20.89bn
Enterprise Value £17.91bn
Revenue £610.1m
Position in Universe 435th / 6853

BRIEF-BeiGene Presents Interim Analysis Results Of Rationale 303 Trial Of Tislelizumab In Second- Or Third-Line Non-Small Cell Lung Cancer At Aacr Annual Meeting

Mon 12th April, 2021 8:07pm
April 12 (Reuters) - Beigene Ltd  6160.HK :
    * BEIGENE PRESENTS INTERIM ANALYSIS RESULTS OF RATIONALE 303
TRIAL
OF TISLELIZUMAB IN SECOND- OR THIRD-LINE NON-SMALL CELL LUNG
CANCER AT AACR ANNUAL MEETING
    * BEIGENE - GLOBAL PHASE 3 TRIAL ACHIEVED PRIMARY ENDPOINT
    * BEIGENE LTD - TISLELIZUMAB WAS GENERALLY WELL-TOLERATED,
CONSISTENT WITH KNOWN RISKS
    * BEIGENE -SUPPLEMENTAL BIOLOGICS APPLICATION BASED ON
RESULTS
FROM RATIONALE 303 TRIAL WAS ACCEPTED IN MARCH 2021 & IS UNDER
REGULATORY REVIEW IN CHINA

Source text for Eikon:  urn:newsml:reuters.com:*:nBwBX675a
Further company coverage:  6160.HK 

 ((Reuters.Briefs@thomsonreuters.com;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.